Press release Biocartis Group NV: Disclosure of transparency notifications
04 Januar 2023 - 05:40PM
GlobeNewswire Inc.
Press release Biocartis Group NV: Disclosure of transparency
notifications
PRESS RELEASE: REGULATED INFORMATION
4
January 2023, 17:40 CET
Disclosure of transparency
notifications
Mechelen, Belgium,
4 January 2023 – Biocartis Group
NV (the ‘Company’ or ‘Biocartis’), an innovative molecular
diagnostics company (Euronext Brussels: BCART), announces today, in
accordance with Article 14, paragraph 1 of the Belgian Act of
2 May 2007 on the disclosure of major shareholdings in issuers of
which shares are admitted to trading on a regulated market and
laying down miscellaneous provisions (the ‘Belgian Transparency
Act’), that it received two transparency notifications dated 21
December 2022 indicating that, on that date, the aggregate number
of voting rights and equivalent financial instruments held by
Heights Capital Management, Inc. (through CVI Investments, Inc.)
was 4.95%, as further explained below. The notifications are based
on a denominator amounting to 92,061,563, it being noted that the
denominator as of today amounts to 92,989,699 as disclosed on 22
December 2022.
The notifications contain the following
information:
- Reason for the
notifications:
Acquisition or disposal of voting securities or voting rights.
-
Notifications
by: A parent undertaking or a controlling
person.
- Person subject to the
notification requirement: Heights Capital Management, Inc,
401 E City Ave, Bala Cynwyd, PA 19004 USA; CVI Investments, Inc,
THE R&H TRUST CO. LTD, P.O. Box 897, Windward 1, Regatta Office
Park, West Bay Road, Grand Cayman, KY1 - 1103, Cayman Islands.
- Transaction
dates: 1 December 2022 (upward crossing
of the 5% notification threshold) and 5 December 2022 (downward
crossing of the 5% notification threshold).
- Threshold that is
crossed: 5%.
- Denominator: 92,061,563.
- Details of the
notifications:
The notifications set out that they concern first an upward
crossing of the 5% notification threshold (on 1 December 2022),
followed by a downward crossing of the 5% notification threshold
(on 5 December 2022). On 21 December 2022, Heights Capital
Management, Inc. held 4.95% of the voting rights in Biocartis
through CVI Investments, Inc.
- Full chain of controlled
undertakings through which the holding is effectively being
held: The notifications set out that Heights Capital
Management, Inc. controls CVI Investments, Inc. Heights Capital
Management Inc. is not controlled.
- Additional
information: CVI Investments, Inc. is the investment
management company that exercises the voting rights at its
discretion in the absence of specific instructions.
For further information, reference is made to
the notifications which are available here on the Biocartis
website.
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the
Company and the Belgian Financial Services and Markets Authority
(‘FSMA’) is required by all natural and legal persons in each case
where the percentage of voting rights in the Company held by such
persons reaches, exceeds or falls below the threshold of 3%, 5%,
10%, and every subsequent multiple of 5%, of the total number of
voting rights in the Company.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com tel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
With its revolutionary and proprietary Idylla™
platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™'s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for COVID-19, Flu,
RSV and sepsis. For more information, visit www.biocartis.com
or follow Biocartis on Twitter @Biocartis_ , Facebook or
LinkedIn.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labelling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2023 bis Apr 2023
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2022 bis Apr 2023